Apnimed, Inc.

APMD

NASDAQHealthcareBiotechnology

在 GoAI 中打开

常规交易时段

US$26.2629

−US$1.7671 · -6.30%

8月24日 14:38 ET

盘中时间采用ET。市场数据可能有所延迟。

公司概况

公司网站

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Kevin R. Lind
上市以来: 2026年7月29日
雇员: 65

市场位置

日内区间

当前US$26.2629，

US$25.70US$27.82

52周区间

当前US$26.2629，

US$16.12US$35.29

开盘价: US$27.82
前收盘价: US$28.03
成交量: 14.22万; 0.28× 平均值
平均成交量: 51.66万; 日均成交量
市值: 10.46亿 USD
贝塔: 0; 市场参考 1
50天平均值: US$28.1294; 低于平均水平-6.64%
200天平均值: US$28.1294; 低于平均水平-6.64%

APMD 消息

247wallst.com2026年8月14日

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).

阅读源码

globenewswire.com2026年8月3日

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral…

阅读源码

reuters.com2026年7月27日

Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO

Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.

阅读源码

seekingalpha.com2026年7月23日

Apnimed Seeks IPO For OSA Treatment Commercialization

Apnimed, Inc. is pursuing an IPO to fund regulatory approval and initial commercialization of its lead OSA drug, Oxnimbi (AD109). AD109 has shown strong efficacy in Phase 3 trials and an FDA decision is expected within a…

阅读源码